Abstracts

870 – Neurocognitive Functioning in Ugandan Youth With HIV: Rural and Urban Differences

Background The influence of sociodemographic (age, sex, education) and HIV factors (viral load, ART regimen) on neurocognition in youth with perinatally acquired HIV (YPHIV) remains unclear due to limited comparison groups. Given large sociodemographic and HIV differences in rural versus urban settings, comparisons between YPHIV from these settings may clarify these effects. In this study,…

1072 – School-Based HIV Prevention for Adolescent Mothers: Population Data From 8 African Countries

Background Adolescent girls in East and Southern Africa (ESA) experience some of the world’s highest HIV incidence, with adolescent mothers representing a particularly vulnerable sub-population. School-based HIV prevention programs can reduce HIV risk by increasing HIV knowledge, promoting safer sexual behaviors, and supporting access to HIV prevention services, including PrEP. However, adolescent mothers, even those…

367 – bNAbs Detected in Tissue Up to 46 Weeks Postadministration

Background Developing functional HIV cure strategies remains a top research priority. Despite promising results from a recent combination immunotherapy trial (NCT04357821, the UCSF-amfAR trial), including a boosted vaccine, TLR9 agonist, and two doses of dual broadly neutralizing antibodies (bNAbs, VRC07-523LS and 10-1074) prior to and at the time of antiretroviral treatment interruption, it remains unclear…

668 – Single-Cell Profiling Reveals a Pathogenic Fibroblast Phenotype in Aortas of Persons With HIV

Background People with HIV (PWH) have a 1.5–2-fold increased risk of atherosclerotic cardiovascular disease. While most studies have focused on immune activation as the primary driver, the contribution of stromal cells, such as fibroblasts and smooth muscle cells, remains underexplored. Fibroblasts are key regulators of extracellular matrix (ECM) remodeling, thrombosis, and vascular inflammation. We hypothesized…

780 – Baseline and Emergent Resistance to BPaL(M) in RR/MDR-TB in PLHIV: Findings From the ADAP-TIV Trial

Background RR/MDR-TB among adults with HIV remains a major clinical and public health challenge in high-burden settings (e.g., South Africa). The rollout of bedaquiline- and pretomanid-based regimens (e.g., BPaL/BPaLM) has revolutionized care, delivering unprecedented safety and efficacy. However, baseline and emergent resistance threaten the long-term durability of these regimens, underscoring the need for surveillance and…

522 – Structural and Functional Insights Into Depulfavirine as an HIV-1 RT Inhibitor

Background Non-nucleoside reverse transcriptase inhibitors (NNRTIs) remain a cornerstone of antiretroviral therapy (ART). Depulfavirine (DPV), the active metabolite of the prodrug elsulfavirine, is a novel NNRTI with favorable pharmacological properties currently under clinical development. While its antiviral potency has been demonstrated, the structural basis of RT inhibition, its biochemical resistance profile, and how DPV behaves…

850 – PK and Safety of Twice-Daily Dolutegravir in 3 kg to 20 kg Children With HIV and TB on Rifampicin

Background Available data supporting global guidelines on the pharmacokinetics and safety of twice daily dolutegravir 10mg dispersible tablets (DT) in children 3-20kg with HIV and tuberculosis (TB) co-infection receiving rifampicin is scarce. We evaluated the pharmacokinetics and safety of twice daily dolutegravir 10mg DT in children 3-20kg on rifampicin. Methods We conducted an open-label, sequential non-randomised prospective study in children initiated on a rifampicin-based TB regimen who concurrently…